Former J&J, Advandx executive appointed as Mylan Specialty president

Roger Graham to lead Mylan subsidiary, maker of EpiPen

PITTSBURGH — Mylan Specialty has appointed Roger Graham as president, the Mylan subsidiary said Monday.

Graham previously worked for Advandx, a privately owned company that develops in-vitro diagnostic tests for infectious diseases and will report to Mylan North America president Tony Mauro. Mylan Specialty markets the EpiPen auto-injector for emergency treatment of severe allergic reactions, among other products.

"Roger's deep brand pharmaceutical industry experience, entrepreneurial mindset and goal-oriented leadership make him the ideal candidate to lead Mylan Specialty as we continue to expand this important business," Mylan CEO Heather Bresch said. "We remain very excited about the growth prospects of the specialty business and are confident that Roger will bring immediate value to our entire North American organization and help accelerate achievement of our ambitions for Mylan Specialty."

Before Advandx, Graham worked for Johnson & Johnson subsidiary Ortho McNeil, leading the company's anti-infective, analgesia and urology business, as well as Roche's central nervous system, pain and dermatology businesses.


Login or Register to post a comment.